Business
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund Operations Through up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious d
About this update from Design Therapeutics, Inc.
[{"type":"image","alt":"Design Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Design Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/756f7355ee3593505f98a201ce9c55ac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8ohx5nSh.dNqlWjduPDJgw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/756f7355ee3593505f98a201ce9c55ac","width":300,"height":72}},"lazy":false},{"type":"text","content":"Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing","length":90,"tagName":"p"},{"type":"text","content":"Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program","length":102,"tagName":"p"},{"type":"text","content":"Well-Capitalized with Cash and Securities of $229.7 Million to Fund Operations Through up to Four Potential Clinical Proof-of-Concept Data Sets","length":143,"tagName":"p"},{"type":"text","content":"CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced progress across its portfolio of GeneTAC® candidates and reported financial results for the first quarter 2025.","length":324,"tagName":"p"},{"type":"text","content":"“Design continued its progress through the first quarter of 2025, marked by the favorable results from our Phase 1 trial in FECD which, in combination with our biomarker studies, support advancing DT-168 into a Phase 2 biomarker trial in patients later this year,” said Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics. “We are also conducting our Phase 1 SAD trial in healthy volunteers for FA, where favorable results would position us to begin a Phase 1/2 trial of DT-216P2 in patients. These programs anchor a differentiated GeneTAC® pipeline that we believe could deliver transformative value in genomic medicine, with the potential for multiple clinical proof-of-concept readouts over the next few years.”","length":745,"tagName":"p"},{"type":"text","content":"Corporate Highlights and Anticipated Upcoming Milestones","length":56,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Frie...